Drug: Tudorza Pressair
Generic molecule: aclidinium bromide
Company: Forest Laboratories
Approval date: July 23
The scoop: The FDA approved this new lung drug, an inhaled treatment for chronic obstructive pulmonary disease, when Forest ($FRX) needed it most. Not only had it lost its patent for the blockbuster Lexapro, but the approval came right in the middle of the company's proxy fight with investor Carl Icahn. Analysts put sales for 2015 at about $250 million, however, filling only a part of the gap left by the newly off-patent antidepressant Lexapro.